Peptide record

TPDB91405

LK15 8R(LR) Antibacterial Antiviral Blood-Brain Barrier Cell-penetrating Peptides Tumor-homing Peptides modified_plain modified
8 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

Standard-residue backbone model; source-recorded chemical modifications are not verified in these coordinates.

TPDB91405
LK15 8R(LR)
Antibacterial Antiviral Blood-Brain Barrier Cell-penetrating Peptides Tumor-homing Peptides
Anti-infective peptides Cancer-related peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP Peptipedia BBPpredict CellPPD CellPPD-MOD CPPsite3.0 PerseuCPP TumorHoPe2.0
modified_plain
Yes
A 8-aa modified multi-activity (Antibacterial, Antiviral, Blood-Brain Barrier, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Chemical: LK15 (L) containing PEGylated nanoparticles
Sequence
RRRRRRRR
Physicochemical Analysis

Sequence-only estimates are not provided for modified or non-standard source notation. Reported molecular properties, when available, are retained below with their source records.

Chemical Descriptors
8 reviewed residue count
Free Activity
LK15 (L) containing PEGylated nanoparticles Activity
L Activity
Cationic Activity
Linear Activity
Free Activity
N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O Activity
Evidence Records 1 records
Evidence 1 Activity

Activity

Cell-penetrating Peptides

Target

Nih3T3 Cells

Assay & Model

6–8 week female BALB/c mice.
6–8 week female BALB/c mice.

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L Cationic
Synthetic
Reporter pDNA encoding GFP
LR peptides (lacking a HS targeting domain) exhibited lower transfection efficiency (12.5 ± 2.9%),
In vitro and in vivo
CCCCCCCC
Additional Detail Fields 1 fields
CCCCCCCC